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Purpose: Phacomatoses are genetic syndromes that are associated with increased risk of devel-
oping nervous system tumors. Phacomatoses are usually inherited, but many develop de novo, 
with unknown etiology. In this population-based study, we investigated the effect of parental 
age on the risk of phacomatoses in offspring.
Patients and methods: The study was a population-based nested case–control study. All indi-
viduals born and residing in Sweden between January 1960 and December 2010 were eligible for 
inclusion. Using the Patient Register, 4625 phacomatosis cases were identified and further classified 
as familial or nonfamilial. Ten matched controls per case were randomly selected from the eligible 
population. Data were analyzed using conditional logistic regression. Analyses were conducted for 
neurofibromatosis alone (n=2089) and other phacomatoses combined (n=2536).
Results: Compared with offspring of fathers aged 25–29 years, increased risk estimates of 
nonfamilial neurofibromatosis were found for offspring of fathers aged 35–39 years (odds 
ratio [OR]=1.43 [95% CI 1.16–1.74]) and ≥40 years (OR =1.74 [95% CI 1.38–2.19]). For other 
nonfamilial phacomatoses, the risk estimate for offspring of fathers aged ≥40 years was OR 
=1.23 (95% CI 1.01–1.50). Paternal age was not associated with familial phacomatoses, and 
no consistent association was observed with maternal age.
Conclusion: The findings show a consistent increase in risk of de novo occurrence of phacomatoses 
predisposing to nervous system tumors in offspring with increasing paternal age, most pronounced 
for neurofibromatosis, while maternal age did not seem to influence the risk. These findings suggest 
an increasing rate of new mutations in the NF1 and NF2 genes in spermatozoa of older fathers.
Keywords: phacomatoses, nervous system tumor predisposition syndromes, parental age, 
registry, neurofibromatosis
Introduction
Genetic syndromes are established risk factors for various diseases, including cancer.1 
Phacomatoses are genetic syndromes with increased cancer susceptibility and are char-
acterized by multiple hamartomas of the central and peripheral nervous system, eye, 
skin, and viscera.2 There are several known phacomatoses that predispose individuals to 
development of nervous system tumors (Table 1), of which neurofibromatosis type 1 and 
type 2 (NF1 and NF2) and tuberous sclerosis complex (TSC) are the most common.3,4
The birth prevalence of NF1, NF2, and TSC is, approximately, 1 in 3000,5 1 in 
35000,3,5 and 1 in 10000,3,6 respectively. They are autosomal dominant disorders; 
however, they develop de novo in a large proportion of patients with no previous 
family history of the disease. It is estimated that ~50% of NF1 and NF2 are de novo 
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occurrences, while for TSC, the majority of cases are de novo 
(~65%–85%).3,4 Furthermore, it is known that some of the de 
novo mutations occur in cells after fertilization, resulting in 
mosaicism, eg, ~30% of de novo NF2 cases are due to mosaic 
mutations,3 while mosaic NF1 occurs less commonly, with 
birth prevalence of 1 in 36000.4
There is some inconclusive evidence on the association 
between perinatal factors, including advanced parental age, 
and phacomatoses in offspring, which is most likely due to 
the increased risk of new germ line mutations.7–9 The available 
studies are very few, are small, and focus on the association 
between parental age and risk of NF1 in offspring.7,8,10,11 In 
addition, it has been shown that perinatal factors, such as 
advanced parental age, are associated with various types 
of pediatric cancer, including nervous system tumors.12–14 
Therefore, the observation of an increased risk of nervous 
system tumors related to advanced parental age, as well as 
related to genetic syndromes, led to the hypothesis that non-
familial genetic syndromes may be associated with advanced 
parental age. Hence, in this study, we investigated the effect of 
parental age on the risk of being born with a genetic syndrome 
associated with the occurrence of nervous system tumors.
Patients and methods
Study subjects and procedures
Study population
The study is designed as a case–control study nested within the 
Swedish population. The eligible population includes individu-
als who were born and resident in Sweden at any time during 
the period between 1 January 1960 and 31 December 2010 with 
information available about parental age for both biological 
parents.15 Informed consent was not required for this study since 
it was register based. The study was approved by the Regional 
Ethical Review Board in Stockholm, and the National Board 
of Health and Welfare assessed patient confidentiality before 
making deidentified and anonymous data available for analyses.
Case identification
Cases were identified through linkage of the population to 
the Patient Register, using the unique personal identifier 
Table 1 Genetic syndromes predisposing to nervous system tumors
Syndrome (OMIM) ICD-9/ICD-
10
Gene Locus Inheritance Nervous system tumors
Neurofibromatosis type 1 
(162200)
237H/Q85.0 NF1 17q11.2 AD Spinal neurofibromas, optic gliomas, 
astrocytomas, meningioma, malignant 
peripheral nerve sheath tumors
Neurofibromatosis type 2 
(101000)
237H/Q85.0 NF2 22q12.2 AD Schwannoma, meningioma, ependymoma, 
astrocytoma
Schwannomatosis 
(162091)
237H/Q85.0 NF2/SMARCB1/? 22q12.2/22q11.23/? AD Schwannoma
Tuberous sclerosis 
complex (191100)
759F/Q85.1 TSC1/TSC2 9q34.13/16p13.3 AD Ependymoma, giant cell astrocytoma, retinal 
astrocytoma
Li-Fraumeni (151623) 759/Q85 TP53/CHEK2 17p13.1 AD Astrocytoma, medulloblastoma
Gorlin (basal cell nevus 
syndrome) (109400)
759/Q85 PTCH1/PTCH2/SUFU 9q22.32/1p34.1/ 
10q24.32
AD Medulloblastoma
Turcot (276300) 759/Q85 APC/hMLH1/hPMS2/ 
hMSH2/hMSH6
5q22.2/3p22.2/7p22. 
1/2p21-p16/2p16.3 
AR Medulloblastoma, astrocytoma, glioblastoma 
multiforme
Cowden (158350) 759/Q85 PTEN 10q23.31 AD Astrocytoma, meningioma
Rubinstein–Taybi 
(180849)
759/Q85 CREBBP 16p13.3 AD Oligodendroglioma, medulloblastoma, 
neuroblastoma, meningioma
Multiple hamartomas 
(601728)
759/Q85 PMS2/PTEN 7p22.2/10q23.31 AD Oligodendroglioma, astrocytoma, meningioma, 
glioblastomas
Ataxia telangiectasia 
(208900)
334W/G11.3 ATM 11q22.3 AR Medulloblastoma, gliomas
von Hippel–Lindau 
(193300)
759G/Q85.8C VHL/CCND1 3p25.3/11q13.3 AD Hemangioblastoma
Carney complex (160980) 759/Q85 PRKAR1A 17q24.2 AD Melanotic schwannoma
Melanoma–astrocytoma 
(155755)
759/Q85 CDKN2A 9p21.3 AD Astrocytoma, medulloblastoma, glioblastoma 
multiforme, ependymoma, glioma, 
meningioma, acoustic neurilemmoma
Hereditary 
retinoblastoma (180200)
759/Q85 RB1 13q14.2 AD Retinoblastoma
Abbreviations: OMIM, Online Mendelian Inheritance in Man; ICD, International Statistical Classification of Diseases and Related Health Problems, Ninth and Tenth 
Revisions; AD, autosomal dominant; AR, autosomal recessive.
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assigned to each Swedish resident. The Patient Register was 
initiated in 1964 and contains information on diagnostic 
codes and surgical procedures for all in-hospital care, avail-
able nationwide since 1987, as well as outpatient specialist 
care with nationwide coverage since 2001.16 Eligible cases of 
neurofibromatosis (NF1, NF2, and schwannomatosis), TSC, 
von Hippel–Lindau disease (VHL), ataxia telangiectasia, and 
other unspecified phacomatoses were identified through the 
Patient Register using the International Statistical Classifica-
tion of Diseases and Related Health Problems, Ninth and Tenth 
Revisions (ICD-9 and ICD-10), as specified in Table 1. Using 
data from the Patient Register gave us a unique opportunity to 
investigate these rare outcomes in a large population with suf-
ficient statistical power. Included cases were individuals born 
in Sweden from 1960 who were still alive in 1987, when the 
ICD-9 version was introduced. As is evident from Table 1, the 
ICD codes do not always distinguish between specific subtypes 
of phacomatoses; hence, it was not possible to specify the 
specific phacomatosis type for 44% of the cases. For neuro-
fibromatosis, the classification in the Patient Register did not 
distinguish between NF1, NF2, and schwannomatosis, but 
the vast majority of neurofibromatosis is NF1 (~90%–95%).17
Determination of heritability
Cases were further classified as familial or nonfamilial. First- 
and second-degree relatives of eligible individuals were identi-
fied through the Multigeneration Register, which includes the 
relationships between parents and their children for all indi-
viduals born since 1932 and resident in Sweden since 1960.18 
Information on occurrence of genetic syndromes in first- and 
second-degree relatives was collected through linkage of the 
identified relatives with the Patient Register. To ensure that 
familial cases were not classified as nonfamilial, we defined 
cases as familial if any genetic syndrome was identified in 
a relative. This conservative approach was used as some of 
the diagnostic information in the Patient Register was coded 
according to earlier, less precise, ICD versions. Thus, for the 
period 1964–1967, ICD-7 code 759, and for 1968–1986, ICD-8 
codes 759, 759.86, 759.87, 743.40 were used to define familial 
occurrence of phacomatosis, whereas from 1987 onward, the 
ICD-9 and ICD-10 codes listed in Table 1 were used.
To assess potential changes in completeness of case 
identification and classification into familial vs nonfamilial 
cases during the study period, we investigated the distribution 
of age at diagnosis according to birth cohort and heritability, 
frequency of identified familial and nonfamilial cases per cal-
endar year, and the distribution of age at death among cases 
according to birth cohort. No apparent trends were observed.
Control selection
Ten controls per case were randomly selected from the eli-
gible population, matched to the case on sex, birth year, and 
residence in Sweden at date of case detection.15 An additional 
eligibility criterion was that controls should not have a first- or 
second-degree relative diagnosed with a genetic syndrome.
Parental age and covariates
Information about parents’ birth years and countries of birth 
was extracted from the Multigeneration Register. Parental 
education and parental country of birth were considered 
potential confounders. Information about parental education 
was collected from registers available at Statistics Sweden. 
We used educational information from the census conducted 
in 1970 and yearly information from the Longitudinal Inte-
gration Database for Health Insurance and Labour Market 
Studies (LISA) from 1990.
Statistical analyses
Conditional logistic regression was used to estimate the crude 
association between parental age and the risk of nonfamilial 
and familial phacomatoses in offspring. The results were 
later adjusted for parental education, parental country of 
birth, and mutually adjusted for maternal and paternal ages. 
Analyses were conducted for neurofibromatosis alone and 
all other phacomatoses combined. Sensitivity analyses were 
performed where the population was restricted to persons 
born 1987 or later. In 1987, the Patient Register became avail-
able nationwide and ICD-9 was introduced, which is likely 
to contribute to a complete case identification and thereby 
less misclassification of heritability. Parental education was 
defined as the highest achieved maternal/paternal educational 
level and was categorized into the following: low, elementary 
school; intermediate, high school or apprenticeship; and 
high, university or postgraduate. Maternal/paternal country 
of birth was categorized into Nordic and non-Nordic coun-
tries, where parental country of birth was considered Nordic 
if both parents were born in a Nordic country. The analyses 
were conducted using Stata statistical software version 13 
(StataCorp, College Station, TX, USA) and SAS statistical 
software version 9.3 (SAS Institute, Inc, Cary, NC, USA).
Results
In total, we identified 4625 phacomatoses cases and 46250 
matched controls. Distribution of phacomatoses subtypes 
was as follows: 2089 neurofibromatosis, of which 61% were 
nonfamilial; and 2536 other subtypes combined, of which 
87% were nonfamilial. More than 45% of the cases were 
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diagnosed with neurofibromatosis. Less than 0.5% of the 
cases and controls had missing data on parental education and 
these were excluded from the analyses. The distributions of 
parental country of birth and parental education were similar 
among cases and controls. The demographic characteristics 
of cases and controls are summarized in Table 2.
Table 3 illustrates the association between paternal and 
maternal ages at birth and prevalence of familial and non-
familial neurofibromatosis in offspring. In crude analyses, 
for offspring of fathers aged 35–39 years, compared with 
offspring of fathers aged 25–29 years, the odds ratio (OR) 
was estimated at 1.44 (95% CI 1.21–1.71), increasing to 
OR =1.72 (95% CI 1.42–2.08) in offspring of fathers aged 
≥40 years. An elevated risk estimate was also observed for 
offspring of mothers aged 35–39 years (OR =1.23 [95% 
CI 1.02–1.49]). We found no indication of associations 
between advanced paternal or maternal age and risk of 
familial neurofibromatosis. In adjusted analyses, compared 
with offspring of fathers aged 25–29 years, elevated risk 
estimates were observed for nonfamilial neurofibromatosis 
among offspring of older fathers; in the category of paternal 
age 35–39 years, the OR was estimated at 1.43 (95% CI 
1.16–1.74), increasing to OR =1.74 (95% CI 1.38–2.19) 
in offspring of fathers aged ≥40 years. No associations 
were observed between advanced paternal age and risk 
of familial neurofibromatosis. Furthermore, there was no 
consistent association between advanced maternal age and 
neurofibromatosis in offspring.
Results for other nonfamilial phacomatoses were simi-
lar but less pronounced (Table 4). For offspring of fathers 
Table 2 Descriptive characteristics of study participants born since 1960
Characteristics NF Nonfamilial 
NF
Familial 
NF
NF-
matched 
controls
Other 
phacomatoses 
combined
Nonfamilial 
phacomatoses
Familial 
phacomatoses
Other 
phacomatoses-
matched controls
Number of 
participants, n (%)
2089 1283 (61) 806 (39) 20890 2536 2195 (87) 341 (13) 25360
Paternal age in 
years, mean, SD
32.13, 0.14 32.61, 0.19 31.35, 0.21 31.40, 0.04 31.37, 0.13 31.41, 0.13 31.17, 0.35 31.14, 0.04
Maternal age in 
years, mean, SD
28.71, 0.12 29.02, 0.15 28.22, 0.18 28.52, 0.04 28.27, 0.11 28.28, 0.11 28.25, 0.28 28.19, 0.03
Sex, n (%)
Male 1051 (50) 657 (51) 394 (49) 10510 (50) 1348 (53) 1169 (53) 179 (52) 13480 (53)
Female 1038 (50) 626 (49) 412 (51) 10380 (50) 1188 (47) 1026 (47) 162 (48) 11880 (47)
Parental education level, n (%)
Lowa 283 (14) 164 (13) 119 (15) 2175 (10) 262 (10) 230 (11) 32 (9) 2530 (10)
Intermediateb 1051 (50) 568 (44) 483 (60) 9603 (46) 1183 (47) 1014 (46) 169 (50) 11925 (47)
Highc 749 (36) 546 (43) 203 (25) 9083 (44) 1089 (43) 950 (43) 139 (41) 10847 (43)
Missing 6 (0) 5 (0) 1 (0) 29 (0) 2 (0) 1 (0) 1 (0) 58 (0)
Parental country of birth,d n (%)
Nordic countries 1809 (87) 1098 (86) 711 (88) 18329 (88) 2261 (89) 1962 (89) 299 (88) 22512 (89)
Non-Nordic 
countries 
280 (13) 185 (14) 95 (12) 2561 (12) 275 (11) 233 (11) 42 (12) 2848 (11)
Missing – – – – – – – –
Birth year, n (%)
1960–1969 355 (17) 240 (19) 115 (14) 3550 (17) 398 (16) 329 (15) 69 (20) 3980 (16)
1970–1979 370 (18) 225 (17) 145 (18) 3700 (18) 469 (18) 408 (19) 61 (18) 4690 (18)
1980–1989 458 (22) 279 (22) 179 (22) 4580 (22) 860 (34) 775(35) 85 (25) 8600 (34)
1990–1999 497 (24) 304 (24) 193 (24) 4970 (24) 635 (25) 543 (25) 92 (27) 6350 (25)
2000–2010 409 (19) 235 (18) 174 (22) 4090 (19) 174 (7) 140 (6) 34 (10) 1740 (7)
Type of phacomatosis, n (%)
Tuberous sclerosis 
complex 
– – – – 376 292 (78) 84 (22) –
von Hippel–Lindau 
disease
– – – – 84 36 (43) 48 (57) –
Ataxia 
telangiectasia 
– – – – 31 22 (71) 9 (29) –
Others – – – – 2045 1845 (90) 200 (10) –
Notes: aLow = elementary school; bIntermediate = high school or apprenticeship; cHigh = university or postgraduate university (parental education was defined by the highest 
household education level); dParental country of birth was considered as Nordic countries if the country of birth of either of the parents was defined as Nordic.
Abbreviation: NF, neurofibromatosis.
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aged ≥40 years, compared with offspring of fathers aged 
25–29 years, the crude OR was estimated at 1.18 (95% CI 
1.00–1.38), whereas the adjusted OR was estimated at 1.23 
(95% CI 1.01–1.50). An elevated risk estimate was also 
observed for offspring of mothers aged <25 years (crude 
OR =1.13 [95% CI 1.01–1.27]; adjusted OR =1.21 [95% CI 
1.06–1.37]), but with no consistent trend. We found no indica-
tion of associations between advanced paternal or maternal 
age and risk of other familial phacomatoses.
Table S1 summarizes the demographic characteristics 
of cases and controls included in the sensitivity analyses 
performed on the subjects born in 1987 or later for whom 
we expect a complete identification of familial cases. The 
associations between advanced paternal age and risk of 
nonfamilial neurofibromatosis, as well as other nonfamilial 
phacomatoses, were more pronounced in analyses restricted 
to subjects born since 1987 (Tables S2 and S3). As in the main 
analyses, no association was observed between advanced 
paternal age and risk of familial neurofibromatosis or 
other familial phacomatoses. Moreover, no association was 
observed with advanced maternal age in adjusted results, 
whereas an indication was found in crude analyses for non-
familial neurofibromatosis (Tables S2 and S3).
Discussion
The results of this study demonstrate that advanced pater-
nal age is associated with an increased risk of nonfamilial 
phacomatoses in children, with a clear trend with increasing 
paternal age. The estimated effect was more pronounced for 
neurofibromatosis than for other types of phacomatoses. For 
nonfamilial neurofibromatosis, no association was observed 
with maternal age, but there was an indication that offspring 
of young mothers had an increased risk of nonfamilial pha-
comatoses other than neurofibromatosis, but with no consis-
tent trend with maternal age. No association was observed 
between parental age and familial phacomatoses in offspring.
Germ cell mutations result from errors in DNA replication, 
and, compared with oogenesis, spermatogenesis consists of 
more cell divisions and consequently more DNA replications. 
Therefore, the de novo mutation rate in the male germ line 
is higher than that in the female germ line, and the mutation 
frequency increases with advancing age.19–21 In addition, there 
is evidence that the majority of de novo NF1 and NF2 muta-
tions are of paternal origin,22,23 which supports our findings 
of an increased risk of de novo neurofibromatosis associated 
with advanced paternal, but not maternal, age. Our findings 
are consistent with an increasing rate of de novo mutations 
in the NF1 and NF2 genes in spermatozoa of older fathers. 
Moreover, most of the germ line mutations involved in various 
subtypes of phacomatosis belong to the Ras pathway genes, 
which are hypothesized to confer a selective advantage in 
terms of de novo mutations for the male gamete.24 However, 
it has also been reported that young maternal age is related 
to some genetic abnormalities and congenital malformations, 
which could be due to disturbances during oocyte matura-
tion.25–27 Moreover, there is evidence that the origin of de novo 
whole-gene deletion of NF1 is predominantly maternal.28
Our findings for neurofibromatosis are in line with the 
results of the study by Liu et al,8 although their substantially 
smaller study did not clearly distinguish between effects of 
paternal and maternal ages. A few previous smaller studies 
also support these findings.7,10,11,29–31 For other subtypes of pha-
comatoses, very few data are available and these do not indi-
cate an effect of parental age. However, these studies included 
few subjects, and analyses were limited to comparison of the 
mean paternal and maternal ages.32–34 Our study represents the 
largest phacomatosis population to date and includes various 
subtypes of phacomatoses. We used population-based regis-
ter data for both case and control recruitment, as well as for 
collection of information about familial conditions, parental 
age, and potential confounding factors, which limits selection 
and recall bias. Parental education and parental country of 
birth were included in the analyses as potential confounders, 
as well as mutual adjustment for maternal and paternal ages, 
respectively, which was not done in most of the previous stud-
ies. As such, we minimized the possibility that the observed 
associations were due to confounding by these factors.
This study has also some limitations. It was not possible 
to distinguish between specific phacomatosis subtypes for 
almost half of the cases due to limitations in the ICD coding 
system used in the Patient Register. The coding allowed us 
to identify neurofibromatosis, but we could not separate the 
specific subtypes of neurofibromatosis, although the majority 
is likely to be NF1 (~95%). Moreover, cases were considered 
familial if their relatives were diagnosed with any type of 
genetic syndromes, again due to the difficulties in specifying 
the phacomatosis subtypes. Access to diagnostic informa-
tion from hospital discharges and outpatient visits gave us a 
unique opportunity to study these rare outcomes in a large 
population with sufficient statistical power and to determine 
whether a case was familial or sporadic. There is, however, 
a possibility that some phacomatosis patients could not be 
identified, especially in the early study period when the Patient 
Register was not yet implemented nationwide. This would 
lead to nondifferential misclassification of the outcome, which 
could bias the risk estimates toward the null. However, the 
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studied outcomes are very rare; thus, the magnitude of such 
bias is likely to be negligible. Of more concern is the poten-
tial misclassification of familial cases as nonfamilial, which 
would dilute the estimates of the effect of paternal age on the 
sporadic occurrence of phacomatoses. Restricting the analyses 
to cases born since the coverage of the Patient Register had 
become nationwide resulted in slightly stronger risk estimates 
associated with paternal age. Thus, our findings are likely to 
be conservative estimates of the effect of paternal age.
Conclusion
In conclusion, the present study provides strong evidence that 
advanced paternal age is associated, in the offspring, with a 
higher prevalence of nonfamilial phacomatoses that are pre-
disposing to nervous system tumors, with the strongest effects 
observed for neurofibromatosis. Our findings did not indicate 
any effect of advanced maternal age on these outcomes.
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Supplementary materials
Table S1 Descriptive characteristics of study participants born since 1987
Characteristics NF Nonfamilial 
NF
Familial 
NF
NF-
matched 
controls
Other 
phacomatoses 
combined
Nonfamilial 
phacomatoses
Familial 
phacomatoses
Other 
phacomatoses-
matched controls
Number of 
participants (%)
1074 644 (60) 430 (40) 10740 1169 1010 (86) 159 (14) 11690
Paternal age in 
years, mean, SD
33.14, 
0.19
33.84, 0.27 32.09, 
0.28
32.42, 
0.06
32.48, 0.18 32.45, 0.19 32.67, 0.49 32.00, 0.06
Maternal age in 
years, mean, SD
29.69, 
0.16
30.16, 0.21 28.97, 
0.24
29.65, 
0.05
29.31, 0.15 29.26, 0.16 29.59, 0.39 29.09, 0.05
Sex, n (%)
Male 578 (54) 365 (57) 213 (50) 5780 (54) 643 (55) 559 (55) 84 (53) 6430 (55)
Female 496 (46) 279 (43) 217 (50) 4960 (46) 526 (45) 451 (45) 75 (47) 5260 (45)
Parental education level, n (%)
Lowa 69 (6) 38 (6) 31 (7) 402 (4) 54 (5) 48 (5) 6 (4) 471 (4)
Intermediateb 547 (51) 278 (43) 269 (63) 4757 (44) 522 (45) 447 (44) 75 (47) 5399 (46)
Highc 456 (43) 326 (51) 130 (30) 5570 (52) 592 (51) 514 (51) 78 (49) 5801 (50)
Missing 2 (0) 2 (0) – 11 (0) 1 (0) 1 (0) – 19 (0)
Parental country of birth,d n (%)
Nordic countries 878 (82) 515 (80) 363 (84) 8855 (82) 990 (85) 863 (85) 127 (80) 9879 (85)
Non-Nordic 
countries
196 (18) 129 (20) 67 (16) 1885 (18) 179 (15) 147 (15) 32(20) 1811 (15)
Birth year, n (%)
1987–1989 168 (16) 105 (16) 63 (15) 1680 (16) 360 (31) 327 (32) 33 (21) 3600 (31)
1990–1999 497 (46) 304 (47) 193 (45) 4970 (46) 635 (54) 543 (54) 92 (58) 6350 (54)
2000–2010 409 (38) 235 (37) 174 (40) 4090 (38) 174 (15) 140 (14) 34 (21) 1740 (15)
Type of phacomatoses, n (%)
Tuberous 
sclerosis complex 
– – – – 220 164 (75) 56 (25) –
von Hippel–
Lindau disease
– – – – 29 6 (21) 23 (79) –
Ataxia 
telangiectasia 
– – – – 12 7 (58) 5 (42) –
Others – – – – 908 833 (92) 75 (8) –
Notes: aLow, elementary school; bIntermediate, high school or apprenticeship; cHigh, university or postgraduate university (parental education was defined by the highest 
household education level); dParental country of birth was considered as Nordic countries if the country of birth of either of the parents was defined as Nordic.
Abbreviation: NF, neurofibromatosis.
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